Sanofi (NASDAQ:SNY) Position Cut by Mondrian Investment Partners LTD

Key Points

• Mondrian Investment Partners LTD reduced its stake in Sanofi by 0.3%, now holding approximately 3.4 million shares, making it the firm's sixth largest position.
• Sanofi reported quarterly earnings of $0.90 EPS, falling short of the $0.96 consensus estimate, despite revenue of $11.34 billion surpassing expectations of $9.91 billion.
• The stock currently holds a consensus rating of "Buy" with a price target averaging $62.00, suggesting optimism among analysts about its future performance.

Mondrian Investment Partners LTD reduced its position in Sanofi (NASDAQ:SNY - Free Report) by 0.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,442,690 shares of the company's stock after selling 10,432 shares during the period. Sanofi accounts for about 3.2% of Mondrian Investment Partners LTD's investment portfolio, making the stock its 6th biggest position. Mondrian Investment Partners LTD owned about 0.14% of Sanofi worth $190,932,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Cardinal Capital Management increased its position in shares of Sanofi by 0.3% during the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock worth $3,827,000 after purchasing an additional 199 shares in the last quarter. Gradient Investments LLC boosted its position in Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after purchasing an additional 200 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares during the period. Beacon Financial Group increased its position in shares of Sanofi by 1.6% in the first quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after buying an additional 222 shares in the last quarter. Finally, AdvisorNet Financial Inc lifted its position in shares of Sanofi by 16.4% during the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock valued at $89,000 after buying an additional 227 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SNY shares. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $62.00.

Sanofi Trading Up 1.5%

SNY traded up $0.73 during trading hours on Friday, reaching $49.77. The company's stock had a trading volume of 2,021,563 shares, compared to its average volume of 2,577,324. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The stock has a market cap of $122.21 billion, a PE ratio of 11.96, a P/E/G ratio of 1.16 and a beta of 0.48. The business's 50-day moving average is $48.58 and its 200-day moving average is $51.85. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company's revenue was down 7.0% on a year-over-year basis. As a group, equities research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.